UroGen Pharma Ltd. (NASDAQ:URGN) Given Average Rating of “Buy” by Brokerages
UroGen Pharma Ltd. (NASDAQ:URGN – Get Free Report) has received an average rating of “Buy” from the six brokerages that are presently covering the company, Marketbeat Ratings reports. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among […]
More Stories
Trump Tells Germany’s Merz to Stop Interfering Over Iran
By Victoria Friedman U.S. President Donald Trump has again criticized German Chancellor Friedrich Merz over Iran, telling Merz to stop...
Trump Signs Order Targeting ‘Bloated Overhead’ in Federal Contracts
By Tom Gantert President Donald Trump signed an executive order Thursday that seeks to address longstanding problems in the federal...
Trump Signs DHS Funding Bill, Ending Shutdown
By Jackson Richman and Joseph Lord President Donald Trump on April 30 signed legislation ending the Department of Homeland Security...
US Economy Rebounds With 2 Percent Growth in 1st Quarter
By Andrew Moran The U.S. economy registered a solid rebound in the first quarter after a disappointing end to 2025,...
Louisiana Governor Signals House Primaries Will Be Postponed After Supreme Court Redistricting Ruling
By Jacki Thrapp Louisiana plans to postpone U.S. House primaries in order to allow time for lawmakers to redraw and...
Top US General Signals Russia Is Helping Iran in War
By Jack Phillips The highest-ranking U.S. general on Thursday signaled that the Russian government is assisting the Iranian regime in...